Company Introduction

BRIM is a new drug biotechnology company. We source first-in-class drugs globally with our experienced team for candidates at pre-clinical stage. Then, we develop projects by collaborating with top CROs and CMOs. Once clinical proof of concept (POC) is reached, we partner out our projects for further clinical development.
全福成立於2013 年，運⽤創新轉譯科學研發模式，專注開發臨床前⾄⼈體臨床藥效驗證階段的新藥。
全福聘任具備國際⼤藥廠新藥開發經驗之經營團隊，建立創新⾼效的營運模式，慎選開發標的、加強專利佈局、配合國際藥政法規、優化研發流程及鏈結國際資源加速產品研發，並以開發具可負擔、⾼品質新藥為願景。
截至目前，全福與合作夥伴簽訂三項創新藥物平台開發案。其中兩項平台衍生成立新創公司先知⽣技，另一項PDSP平台已開發出三項first-in-class治療病因的創新藥物，其中乾眼症藥物BRM421正積極籌備申請美國臨床三期試驗許可，並期盡快推進藥物上市，讓病人受惠。

Brief description of main products or services 

BRM421 is a first-in-class, novel neurotrophic peptide drug for dry eye syndrome. BRIM completed its second-in-human Phase 2/3 trial in Q32020. Key clinical findings of the completed Ph2/3 trial:
A) Early onset: BRM421 shows efficacy in 2 weeks while current approved drug need 3-6 months
B) Novel MoA: BRM421 has cornea repair functions while other approved drugs have either tear volume or anti-inflammation
C) Great safety: No patient withdraws due to AEs